Effects of Breadfruit and Cocoyam Starch Mucilage Binders. On Disintegration and Dissolution Behaviors of Paracetamol Tablet Formulations.

Adebayo,A.S.;

Effects of Breadfruit and Cocoyam Starch Mucilage Binders. On Disintegration and Dissolution Behaviors of Paracetamol Tablet Formulations.

March 2, 2003

By A.S. Adebayo, PhD

Publication

Article

Pharmaceutical TechnologyPharmaceutical Technology-03-02-2003

Volume 27

Issue 3

Binder properties of mucilage of starches extracted from breadfruit and cocoyam were investigated in paracetamol tablet formulations using tablet physical properties, disintegration times, and dissolution rates as assessment parameters.

External Link - article-49252.pdf

Articles in this issue

The Clarification of Bioreactor Cell Cultures for Biopharmaceuticals

Standards for Supplements

Concept Paper Discusses Update of Aspetic Processing Guidelines

Outsourcing Outlook March 2003

A Review of Classification of Emerging Excipients in Parenteral Medications

March 2003

Effects of Breadfruit and Cocoyam Starch Mucilage Binders. On Disintegration and Dissolution Behaviors of Paracetamol Tablet Formulations.

Related Content

The mRNA or messenger Ribonucleic Acid white text for medical or outbreak concept 3d rendering | Image Credit: ©niphon - adobe.stock.com

Looking Beyond mRNA-based COVID-19 Vaccines to Innovative Therapeutics

Cheryl Barton

June 24th 2025

Article

mRNA technologies offer great promise in immunotherapy and non-immunogenic applications.

Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development

March 26th 2024

Podcast

In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.

Science laboratory test tubes, laboratory equipment | Image Credit: © BillionPhotos.com - © BillionPhotos.com - stock.adobe.com

AstraZeneca and Alteogen Sign License Agreement for Developing Subcutaneous Formulations of Oncology Assets

Feliza Mirasol

March 25th 2025

Article

Under the agreement, AstraZeneca will use Alteogen’s proprietary hyaluronidase platform technology to develop and commercialize subcutaneous formulations of multiple oncology assets in its portfolio.